A Multicenter Study With an Open Label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics (PK) of M3814 in Combination With Etoposide and Cisplatin in Subjects With SCLC Extensive Disease (ED).

Trial Profile

A Multicenter Study With an Open Label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics (PK) of M3814 in Combination With Etoposide and Cisplatin in Subjects With SCLC Extensive Disease (ED).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs M 3814 (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors EMD Serono Research & Development Institute
  • Most Recent Events

    • 10 May 2017 Status changed from not yet recruiting to recruiting.
    • 19 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top